GLPBio

Vincristine

Catalog No.: GC38410Purity:>98.00%
Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32μM in a cell-free assay. Vincristine can induces apoptosis.

Products are for research use only. Not for human use. We do not sell to patients.


Vincristine
Cas No.: 57-22-7
1mgIn Stock
$36.00
1
5mgIn Stock
$61.00
1
10mgIn Stock
$102.00
1
20mgIn Stock
$183.00
1

Citations

3 publicationsPublications from researchers using this product

Description

Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32μM in a cell-free assay. Vincristine can induces apoptosis[1].

Vincristine (100nM; 48h) induces distinct death programs in primary ALL cells depending on cell cycle phase, and cells in G1 are susceptible to perturbation of interphase microtubules[2].Vincristine (5nM; 4, 8, 24h) triggers a cascade of axon pathology, causing mitochondrial dysfunction that leads to elevated axonal ROS levels and SARM1-dependent axon degeneration[3].Vincristine (0.3-10nM; 48h) and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway[4].

Vincristine (Pre: <10μg or 0.5mg/kg; Post: 10μg; ip; 25d) causes swelling and redness of the injected paw as well as a strong dose-dependent infiltration of immune cells to the site of injection. Consistent with the neuro-inflammatory signature, mechanical allodynia was decreased in mice lacking Tlr4, as well as in mice treated with minocycline[5].Vincristine (3mg/kg; iv; 1 time) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52day, and repopulating fractions of 0.06% and 5%, respectively[6].

References:
[1].Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, Vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985 Jun;45(6):2741-7.
[2].Kothari A, Hittelman W N, Chambers T C. Cell cycle–dependent mechanisms underlie Vincristine-induced death of primary acute lymphoblastic leukemia cells[J]. Cancer research, 2016, 76(12): 3553-3561.
[3].Gomez-Deza J, Slavutsky A L, Nebiyou M, et al. Local production of reactive oxygen species drives Vincristine-induced axon degeneration[J]. Cell Death & Disease, 2023, 14(12): 807.
[4].Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM. The synergic effect of Vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol. 2015 Jul 10;8:82.
[5].Starobova H, Mueller A, Allavena R, et al. Minocycline prevents the development of mechanical allodynia in mouse models of Vincristine-induced peripheral neuropathy[J]. Frontiers in Neuroscience, 2019, 13: 653.
[6].Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482-7.

Protocol

Cell experiment [1]:

Cell lines

ALL-2 cells

Preparation Method

The ALL-2 cells in either G1 or G2/M phases were treated with vehicle (0.1% DMSO) or 100nM Vincristine, harvested at specific times, and DNA content analyzed.

Reaction Conditions

100nM; 48h

Applications

When treated with Vincristine, cells underwent M phase arrest, with 86.4% cells having 4N DNA content within 8h of Vincristine treatment, and by 48h, 50% of cells had <2N DNA content.
Animal experiment [2]:

Animal models

Vincristine-induced peripheral neuropathy (VIPN) Model

Preparation Method

Vincristine (<10μg; ip; or 0.5mg/kg; ip) or vehicle (PBS; ip) were administered for five consecutive days, with 2 days break, followed by another five consecutive injections. The highest Vincristine dose (10μg; ip) was administered for four consecutive days, followed by 5 days break and another two injections. Minocycline (25mg/kg; ip) was administered once daily, 3 days before Vincristine administration, and then with each Vincristine injection.

Dosage form

1-12 days: <10μg or 0.5mg/kg; 12-25 days: 10μg; ip; 25 days

Applications

Injection of Vincristine causes swelling and redness of the injected paw as well as a strong dose-dependent infiltration of immune cells to the site of injection. Consistent with the neuro-inflammatory signature, mechanical allodynia was decreased in mice lacking Tlr4, as well as in mice treated with minocycline.

References:
[1].Kothari A, Hittelman W N, Chambers T C. Cell cycle–dependent mechanisms underlie Vincristine-induced death of primary acute lymphoblastic leukemia cells[J]. Cancer research, 2016, 76(12): 3553-3561.
[2].Starobova H, Mueller A, Allavena R, et al. Minocycline prevents the development of mechanical allodynia in mouse models of Vincristine-induced peripheral neuropathy[J]. Frontiers in Neuroscience, 2019, 13: 653.

Product Documents

Purity:>98.00%Appearance:A solid

Chemical Properties

CAS No.
57-22-7
SMILES
CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O
Molecular Formula
C46H56N4O10
Molecular Weight
824.96
Solubility
Soluble in DMSO
Storage
Store at -20°C, protect from light
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Vincristine

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%